Karl Deonanan has extensive experience in financial leadership, currently serving as Chief Financial Officer at Precision Medicine Group since September 2024. Prior to this role, Karl held CFO positions at ProPharma, X-Chem, Inc., and Synteract, showcasing a solid track record in financial management within the pharmaceutical and biotech sectors. Additional significant roles include various positions at QuintilesIMS and Quintiles, where Karl contributed to investor relations and finance management across regions and departments. Karl's early career involved auditing at Arthur Andersen and Dixon Hughes Goodman LLP. Academic credentials include a Master of Science in Accounting from East Carolina University and a Bachelor of Science in Accounting from the University of North Carolina Wilmington.